134 related articles for article (PubMed ID: 32372027)
1. Clinical utility of serial analysis of circulating tumour cells for detection of minimal residual disease of metastatic nasopharyngeal carcinoma.
Ko JM; Vardhanabhuti V; Ng WT; Lam KO; Ngan RK; Kwong DL; Lee VH; Lui YH; Yau CC; Kwan CK; Li WS; Yau S; Guo C; Choi SSA; Lei LC; Chan KC; Lam CC; Chan CK; Dai W; Khong PL; Lung ML
Br J Cancer; 2020 Jul; 123(1):114-125. PubMed ID: 32372027
[TBL] [Abstract][Full Text] [Related]
2. Relationship of circulating tumor cells and Epstein-Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients.
You R; Liu YP; Lin M; Huang PY; Tang LQ; Zhang YN; Pan Y; Liu WL; Guo WB; Zou X; Zhao KM; Kang T; Liu LZ; Lin AH; Hong MH; Mai HQ; Zeng MS; Chen MY
Int J Cancer; 2019 Nov; 145(10):2873-2883. PubMed ID: 31044420
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor cells with karyotyping as a novel biomarker for diagnosis and treatment of nasopharyngeal carcinoma.
Zhang J; Shi H; Jiang T; Liu Z; Lin PP; Chen N
BMC Cancer; 2018 Nov; 18(1):1133. PubMed ID: 30454007
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of Excision Repair Cross-Complementation Group 1 on Circulating Tumor Cells for Nasopharyngeal Carcinoma.
Liu T; Li Y; Song J; Li B; Wang R; Huang T; Qin Y
Cancer Control; 2024; 31():10732748241251562. PubMed ID: 38716503
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of COX-2 expression on circulating tumor cells in nasopharyngeal carcinoma: A prospective analysis.
Li YJ; Luo Y; Xie XQ; Li P; Wang F
Radiother Oncol; 2018 Nov; 129(2):396-402. PubMed ID: 30082142
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
7. Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy.
Lin SY; Chang SC; Lam S; Irene Ramos R; Tran K; Ohe S; Salomon MP; Bhagat AAS; Teck Lim C; Fischer TD; Foshag LJ; Boley CL; O'Day SJ; Hoon DSB
Clin Chem; 2020 Jan; 66(1):169-177. PubMed ID: 31672856
[TBL] [Abstract][Full Text] [Related]
8. The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer.
Stefanovic S; Deutsch TM; Riethdorf S; Fischer C; Hartkopf A; Sinn P; Feisst M; Pantel K; Golatta M; Brucker SY; Sütterlin M; Schneeweiss A; Wallwiener M
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245182
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of circulating tumor cell measurement in the peripheral blood of patients with nasopharyngeal carcinoma.
Gao T; Mao J; Huang J; Luo F; Lin L; Lian Y; Bin S; Zhao L; Li S
Clinics (Sao Paulo); 2023; 78():100179. PubMed ID: 36963168
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor Cells and Fibronectin 1 in the Prognosis of Nasopharyngeal Carcinoma.
Yu Y; Lin ZX; Li HW; Luo HQ; Yang DH; Zhou HC; Jiang DX; Zhan DC; Yang L; Liang XY; Yu ZH; Chen ZH
Technol Cancer Res Treat; 2020; 19():1533033820909911. PubMed ID: 32281480
[TBL] [Abstract][Full Text] [Related]
11. The association between circulating tumor cells and Epstein-Barr virus activation in patients with nasopharyngeal carcinoma.
He C; Huang X; Su X; Tang T; Zhang X; Ma J; Guo X; Lv X
Cancer Biol Ther; 2017 Nov; 18(11):888-894. PubMed ID: 28121221
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells: a valuable marker of poor prognosis for advanced nasopharyngeal carcinoma.
Ou G; Xing S; Li J; Zhang L; Chen S
Mol Med; 2019 Nov; 25(1):50. PubMed ID: 31729954
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
14. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
[TBL] [Abstract][Full Text] [Related]
15. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
Bian J; Yan K; Liu N; Xu X
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2621-2630. PubMed ID: 32661602
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy.
Vo JH; Nei WL; Hu M; Phyo WM; Wang F; Fong KW; Tan T; Soong YL; Cheah SL; Sommat K; Low H; Ling B; Ng J; Tan WL; Chan KS; Oon L; Ying JY; Tan MH
Sci Rep; 2016 Dec; 6(1):13. PubMed ID: 28442757
[TBL] [Abstract][Full Text] [Related]
17. Joint quantitative measurement of hTERT mRNA in both peripheral blood and circulating tumor cells of patients with nasopharyngeal carcinoma and its clinical significance.
Fu X; Shen C; Wang H; Chen F; Li G; Wen Z
BMC Cancer; 2017 Jul; 17(1):479. PubMed ID: 28693532
[TBL] [Abstract][Full Text] [Related]
18.
Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
[No Abstract] [Full Text] [Related]
19. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
[TBL] [Abstract][Full Text] [Related]
20. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
